In this study, we observed that FOXP1 is highly upregulated in gemcitabine-resistant (GR) pancreatic cancer and that higher FOXP1 expression leads to unfavorable patient outcomes. The gene discussed is FOXP1; the disease is familial pancreatic carcinoma.